Table 1 Demographic and survival difference between sedated and non-sedated patients
Variables | Total | Sedated(N = 82) | Non-sedated(N = 162) | P value |
|---|---|---|---|---|
Total | 244 | 82 | 162 | - |
Mean age (years) | 63 | 62 | 63 | 0.86 |
Gender (male/female) | 125/119 | 40/42 | 85/77 | 0.34 |
KPS (median) | 20 | 20 | 30 | 0.12 |
Primary tumor site (N/%) | 0.60 | |||
Lung cancer | 36 | 12/14.6% | 24/14.8% | |
Liver cancer | 30 | 12/14.6% | 18/11.1% | |
Breast cancer | 26 | 8/9.8% | 18/11.1% | |
Stomach cancer | 33 | 9/11.0% | 24/14.8% | |
Colon cancer | 22 | 8/9.8% | 14/8.6% | |
Nasopharyngeal cancer | 6 | 2/2.4% | 4/2.5% | |
Kidney/Prostate cancer | 17 | 5/6.1% | 12/7.4% | |
Pancreas | 20 | 7/8.5% | 13/8.0% | |
Gallbladder | 9 | 3/3.7% | 6/3.7% | |
Hematological Cancer | 4 | 2/2.4% | 2/1.2% | |
Female genital tract cancer | 20 | 8/9.8% | 12/7.4% | |
Primary unknown | 7 | 2/2.4% | 5/3.1% | |
Others | 12 | 2/2.4% | 10/6.2% | |
Survival time (days)(mean) (95CI)* | 23.54 | 27.44 (23.2-31.65) | 21.56 (18.52-24.59) | 0.066 |
Total Survival time (months)(mean) (95CI )# | 25.86 | 35.65 (26.55-44.75) | 20.90 (16.72-25.10) | 0.002 |